Left Ventricular Hypertrophy and Arrhythmogenesis

Cardiac Electrophysiology Clinics

Volumn 7, Issue 2, 2015, Pages 207-220

  Shenasa, Mohammad ^a,b   Shenasa, Hossein ^a,b   El Sherif, Nabil ^c,d  

^a O'Connor Hospital California   (United States)

^b Heart and Rhythm Medical Group   (United States)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Arrhythmogenesis; Atrial fibrillation; Hypertension; Hypertensive heart disease; Left ventricular hypertrophy; Torsades de pointes; Ventricular arrhythmias

Indexed keywords

LOSARTAN;

ARRHYTHMOGENESIS; CARDIAC IMAGING; CARDIOVASCULAR MAGNETIC RESONANCE; COMPUTER ASSISTED TOMOGRAPHY; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY; HEART ATRIUM ARRHYTHMIA; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; LONG TERM CARE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VALVULAR HEART DISEASE; HEART ARRHYTHMIA; TORSADE DES POINTES;

ARRHYTHMIAS, CARDIAC; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; TORSADES DE POINTES;

EID: 84930276524     PISSN: 18779182     EISSN: 18779190     Source Type: Journal    
DOI: 10.1016/j.ccep.2015.03.017     Document Type: Review

References (103)

1. Mirvis D.M., Goldberger A.L. Electrocardiography. Braunwald's heart disease: a textbook of cardiovascular medicine 2015, 114-154. Elsevier, Philadelphia. 10th edition.
2. Sokolow M., Lyon T.P. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J 1949, 37(2):161-186.
3. Romhilt D.W., Bove K.E., Norris F.J., et al. Acritical appraisal of the electrocardiographic criteria for the diagnosis of left ventricular hypertrophy. Circulation 1969, 40(2):185-195.
4. Butler P.M., Legget S.I., Howe C.M., et al. Identification of electrocardiographic criteria for diagnosis of right ventricular hypertrophy due to mitral stenosis. Am J Cardiol 1986, 57(8):639-643.
5. Lorenz C.H., Walker E.S., Morgan V.L., et al. Normal human right and left ventricular mass, systolic function, and gender differences by cine magnetic resonance imaging. JCardiovasc Magn Reson 1999, 1:7-21.
6. Lorell B., Carabello B. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 2000, 102:470-479.
7. Chambers J. Left ventricular hypertrophy: an underappreciated coronary risk factor. BMJ 1995, 311:273-274.
8. Okin P.M., Devereux R.B., Nieminen M.S., et al. Electrocardiographic strain pattern and prediction of cardiovascular morbidity and mortality in hypertensive patients. Hypertension 2004, 44:48-54.
9. Levy D., Labib S., Anderson K., et al. Determinants of sensitivity and specificity of electrocardiographic criteria for left ventricular hypertrophy. Circulation 1990, 81:815-820.
10. Macfarlane P. Is electrocardiography still useful in the diagnosis of cardiac chamber hypertrophy and dilatation?. Cardiol Clin 2006, 24:401-411.
11. Prisant M. Hypertensive heart disease. JClin Hypertens 2005, 7:231-238.
12. Shenasa M., Shenasa H. Electrocardiographic markers of sudden cardiac death in different substrates. The ECG handbook of contemporary challenges 2015, Cardiotext, Minneapolis, MN, Chapter 6.
13. Levy D., Savage D.D., Garrison R.J., et al. Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol 1987, 59:956-960.
14. Levy D., Murabito J.M., Anderson K.M., et al. Echocardiographic left ventricular hypertrophy: clinical characteristics: the Framingham Heart Study. Clin Exp Hypertens 1992, 14:85-97.
15. Kannel W., Gordon T., Castelli W.P., et al. Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. The Framingham Study. Ann Intern Med 1970, 72(6):813-822.
16. Solomon S.D., Wu J., Gillam L. Echocardiography. Braunwald's heart disease: a textbook of cardiovascular medicine 2015, Elsevier, Philadelphia. 10th edition.
17. Feingenbaum H., Armstrong W., Ryan T. Feigenbaum's echocardiography 2005, Lippincott William & Wilkins, Philadelphia. 6th edition.
18. Oh J.K., Seward J.B., Tajik A.J. The Echo manual 2006, Lippincott William & Wilkins, Philadelphia. 3rd edition.
19. Kahan T., Bergfeldt L. Left ventricular hypertrophy in hypertension: its arrhythmogenic potential. Heart 2005, 91:250-256.
20. Giannakidis A., Rohmer D., Veress A., et al. Diffusion tensor magnetic resonance imaging-derived myocardial fiber disarray in hypertensive left ventricular hypertrophy; visualization, quantification and the effect on mechanical function. Cardiac mapping 2013, 574-588. Wiley-Blackwell, Oxford, UK, Chapter 53. 4th edition. M. Shenasa, G. Hindricks, M. Borggrefe (Eds.).
21. Lacchini R., Luizon M., Gasparini S., et al. Effect of genetic polymorphisms of vascular endothelial growth factor on left ventricular hypertrophy in patients with systemic hypertension. Am J Cardiol 2014, 113:491-496.
22. Diez J., Frohlich E.D. Atranslational approach to hypertensive heart disease. Hypertension 2010, 55:1-8.
23. Lips D., deWindt L.J., Kraaij D., et al. Molecular determinants of myocardial hypertrophy and failure: alternative pathways for beneficial and maladaptive hypertrophy. Eur Heart J 2003, 24:883-896.
24. Kehat I., Molkentin J.D. Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation 2010, 122:2727-2735.
25. Yuda S., Khoury V., Marwick T.H. Influence of wall stress and left ventricular geometry on the accuracy of dobutamine stress echocardiography. JAm Coll Cardiol 2002, 40:1311-1319.
26. Lavie C.J., McAuley P.A., Church T.S., et al. Obesity and cardiovascular diseases: implications regarding fitness, fatness, and severity in the obesity paradox. JAm Coll Cardiol 2014, 63:1345-1354.
27. Schlaich M.P., Kaye D.M., Lambert E., et al. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 2003, 108:560-565.
28. Zilinski J., Contursi M., Isaacs S., et al. Myocardial adaptation to recreational marathon training among middle-aged men. Circ Cardiovasc Imaging 2015, 8:e002487.
29. Maron B., Pelliccia A. The heart of trained athletes: cardiac remodeling and the risks of sports including sudden death. Circulation 2006, 114:1633-1644.
30. Yilmaz A., Sechtem U. Diagnostic approach and differential diagnosis in patients with hypertrophied left ventricles. Heart 2014, 100:662-671.
31. Namdar M., Steffel J., Jetzer S., et al. Value of electrocardiogram in the differentiation of hypertensive heart disease, hypertrophic cardiomyopathy, aortic stenosis, amyloidosis, and Fabry disease. Am J Cardiol 2012, 109:587-593.
32. Puntmann V.O., Jahnke C., Gebker R., et al. Usefulness of magnetic resonance imaging to distinguish hypertensive and hypertrophic cardiomyopathy. Am J Cardiol 2010, 106:1016-1022.
33. Kobza R., Cuculi F., Abacherli R., et al. Twelve-lead electrocardiography in the young: physiologic and pathologic abnormalities. Heart Rhythm 2012, 9(12):2018-2022.
34. Drazner M.H. The progression of hypertensive heart disease. Circulation 2011, 123:327-334.
35. Frohlich E.D., Apstein C., Chobanian A.V., et al. The heart in hypertension. NEngl J Med 1992, 327:998-1008.
36. Schillaci G., Verdecchia P., Porcellati C., et al. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 2000, 35:580-586.
37. Fox E., Musani S., Samdarshi T., et al. Clinical correlates and prognostic significance of change in standardized left ventricular mass in a community-based cohort of African Americans. JAm Heart Assoc 2015, 4:e001224.
38. Drazner M.H., Dries D.L., Peshock R.M., et al. Left ventricular hypertrophy is more prevalent in blacks than whites in the general population: the Dallas Heart Study. Hypertension 2005, 46:124-129.
39. Ichikawa K.I., Hidai C., Okuda C., et al. Endogenous endothelin-1 mediates cardiac hypertrophy and switching of myosin heavy chain gene expression in rate ventricular myocardium. JAm Coll Cardiol 1996, 27:1286.
40. Xin W., Toshio N., Kazumi A., et al. Upregulation of ligand, receptor system, and amidating activity of adrenomedullin in left ventricular hypertrophy of severely hypertensive rats: effects of angiotensin-converting enzyme inhibitors and diuretic. Hypertension 2003, 21(6):1171-1181.
41. Haider A., Larson M., Benjamin E., et al. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. JAm Coll Cardiol 1998, 32:1454-1459.
42. Narayanan K., Reinier K., Teodorescu C., et al. Electrocardiographic versus echocardiographic left ventricular hypertrophy and sudden cardiac arrest in the community. Heart Rhythm 2014, 11:1040-1046.
43. Laukkanen J., Khan H., Kurl S., et al. Left ventricular mass and the risk of sudden cardiac death: a population-based study. JAm Heart Assoc 2014, 3:e001285.
44. Stevens S., Reinier K., Chugh S. Increased left ventricular mass as a predictor of sudden cardiac death: is it time to put it to the test?. Circ Arrhythm Electrophysiol 2013, 6:212-217.
45. Soliman E., Shah A., Boerkircher A., et al. Inter-relationship between electrocardiographic left ventricular hypertrophy and QT prolongation as predictors of increased risk of mortality in the general population. Circ Arrhythm Electrophysiol 2014, 7:400-406.
46. Okin P.M., Bang C.N., Wachtell K., et al. Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy. Circ Arrhythm Electrophysiol 2013, 6:243-251.
47. Raman S.V. The hypertensive heart: an integrated understanding informed by imaging. JAm Coll Cardiol 2010, 55:91-96.
48. Verdecchia P., Reboldi R., Bentivoglio M., et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension 2003, 41:218-223.
49. Kannel W.B., Abbott R.D., Savage D.D., et al. Epidemiologic features of chronic atrial fibrillation: the Framingham Study. NEngl J Med 1982, 306:1018.
50. Chrispin J., Jain A., Soliman E.Z., et al. Association of electrocardiographic and imaging surrogates of left ventricular hypertrophy with incident atrial fibrillation: MESA (Multi-Ethnic Study of Atherosclerosis). JAm Coll Cardiol 2014, 63:2007-2013.
51. Chatterjee S., Bavishi C., Sardar P., et al. Meta-Analysis of left ventricular hypertrophy and sustained arrhythmias. Am J Cardiol 2014, 114:1049-1052.
52. Gillis A.M., Mathison H.J., Kulisz E., et al. Dispersion of ventricular repolarization and ventricular fibrillation in left ventricular hypertrophy: influence of selective potassium channel blockers. JPharmacol Exp Ther 2000, 292:381-386.
53. Kulan K., Ural D., Komsuoğlu B., et al. Significance of QTc prolongation on ventricular arrhythmias in patients with left ventricular hypertrophy secondary to essential hypertension. Int J Cardiol 1998, 64:179-184.
54. Lee S.W., Schwartz A., Adams R.J., et al. Decrease in Na+,K+-ATPase activity and [3H]ouabain binding sites in sarcolemma prepared from hearts of spontaneously hypertensive rats. Hypertension 1983, 5:682-688.
55. Cameron J.S., Kimura S., Jackson-Burns D.A., et al. ATP-sensitive K+ channels are altered in hypertrophied ventricular myocytes. Am J Physiol 1988, 255(5 Pt 2):H1254-H1258.
56. Panyasing Y., Kijtawornrat A., Del rio C., et al. Uni- or bi-ventricular hypertrophy and susceptibility to drug-induced torsades de pointes. JPharmacol Toxicol Methods 2010, 62:148-156.
57. Ben-David J., Zipes D.P., Ayers G.M., et al. Canine left ventricular hypertrophy predisposes to ventricular tachycardia induction by phase 2 early after depolarizations after administration of BAY K 8644. JAm Coll Cardiol 1992, 20:1576-1584.
58. Rials S.J., Wu Y., Ford N., et al. Effect of left ventricular hypertrophy and its regression on ventricular electrophysiology and vulnerability to inducible arrhythmia in the feline heart. Circulation 1995, 91:426-430.
59. Rials S.J., Wu Y., Xu X., et al. Regression of left ventricular hypertrophy with captopril restores normal ventricular action potential duration, dispersion of refractoriness, and cardiac death after coronary artery occlusion in conscious dogs. Circulation 1982, 65:1192-1197.
60. Peters N.S., Green C.R., Poole-Wilson P.A., et al. Reduced content of connexin43 gap junctions in ventricular myocardium from hypertrophied and ischemic human hearts. Circulation 1993, 88:864-875.
61. Weber K.T., Brilla C.G. Pathological hypertrophy and cardiac interstitium. Fibrosis and rennin-angiotensin-aldosterone system. Circulation 1991, 83:1849-1865.
62. Gaudesius G., Miragoli M., Thomas S.P., et al. Coupling of cardiac electrical activity over extended distances by fibroblasts of cardiac origin. Circ Res 2003, 93:421-428.
63. Wolk R. Arrhythmogenic mechanisms in left ventricular hypertrophy. Europace 2000, 2:216-223.
64. Ferrara L.A., Mancini M., de Simone G., et al. Adrenergic nervous system and left ventricular mass in primary hypertension. Eur Heart J 1989, 10:1036-1040.
65. Kelm M., Schäfer S., Mingers S., et al. Left ventricular mass is linked to cardiac noradrenaline in normotensive and hypertensive patients. JHypertens 1996, 14:1357-1364.
66. Barron H.V., Lesh M.D. Autonomic nervous system and sudden cardiac death. JAm Coll Cardiol 1996, 27:1053-1060.
67. Antoons G., Oros A., Bito V., et al. Cellular basis for triggered ventricular arrhythmias that occur in the setting of compensated hypertrophy and heart failure: consideration for diagnosis and management. JElectrocardiol 2007, 40:S8-S14.
68. Arnett D.K., Li N., Tang W., et al. Genome-wide association study identifies single-nucleotide polymorphism in KCNB1 associated with left ventricular mass in humans: the HyperGEN Study. BMC Med Genet 2009, 10:43.
69. Arnett D.K., de las Fuentes L., Broeckel U. Genes for left ventricular hypertrophy. Curr Hypertens Rep 2004, 6:36-41.
70. Levy D., Anderson K.M., Savage D.D., et al. Risk of ventricular arrhythmia in left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol 1987, 60:560-565.
71. Koyanagi S., Eastham C., Marcus M.L. Effects of chronic hypertension and left ventricular hypertrophy on the incidence of sudden cardiac death after coronary artery occlusion in conscious dogs. Circulation 1982, 55:1192-1197.
72. Martins J.B., Kim W., Marcus M.L. Chronic hypertension and left ventricular hypertrophy facilitate induction of sustained ventricular tachycardia in dogs three hours after left circumflex coronary artery disease. JAm Coll Cardiol 1989, 14:365-373.
73. Kohya T., Kimura S., Myerburg R.J., et al. Susceptibility of hypertrophied rat hearts to ventricular fibrillation during acute ischemia. JMol Cell Cardiol 1988, 20:159-168.
74. Nguyen T., Salibi E.E., Rouleau J.L. Post infarction survival and inducibility of ventricular arrhythmias in the spontaneously hypertensive rat. Effects of ramipril and hydralazine. Circulation 1998, 98:2074-2080.
75. Wolk R., Sneddon K.P., Dempster J., et al. Regional electrophysiological effects of left ventricular hypertrophy in isolated rabbit hearts under normal and ischemic conditions. Cardiovasc Res 2000, 48:120-128.
76. Koshevnikov D., Caref E.B., El-Sherif N. Mechanisms of enhanced arrhythmogenecity of regional ischemia in the hypertrophied heart. Heart Rhythm 2009, 6:522-527.
77. Vermeulen J.T., Hanno T.L., Rademaker H. Electrophysiologic and cellular ionic changes during acute ischemia in failing and normal rabbit myocardium. JMol Cell Cardiol 1996, 28:123-131.
78. Furukawa T., Myerburg R.J., Furukawa N., et al. Metabolic inhibition of ICa-L and IK differs in feline left ventricular hypertrophy. Am J Physiol 1994, 266:H1121-H1131.
79. Janse J., Van capelle F.J., Morsink H., et al. Flow of "injury" current and pattern of excitation during early ventricular arrhythmias in acute regional myocardial ischemia in isolated porcine and canine hearts. Circ Res 1980, 47:151-165.
80. Choi B.R., Salama G. Simultaneous maps of optical action potentials and calcium transients in guinea-pig hearts: mechanisms underlying concordant alternans. JPhysiol (London) 2000, 529:171-188.
81. Lakireddy V., Baweja P., Syed A., et al. Contrasting effects of ischemia on the kinetics of membrane voltage and intracellular calcium transient underlie electrical alternans. Am J Physiol Heart Circ Physiol 2005, 288:H400-H407.
82. Bacharova L., Chen H., Estes H., et al. Determinants of discrepancies in detection and comparison of the prognostic significance of left ventricular hypertrophy by electrocardiogram and cardiac magnetic resonance imaging. Am J Cardiol 2015, 115(4):515-522.
83. Levy D., Garrison R.J., Savage D.D., et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. NEngl J Med 1990, 322:1561-1566.
84. Vakili B.A., Okin P.M., Devereux R.B. Prognostic implications of left ventricular hypertrophy. Am Heart J 2001, 141:334-341.
85. Krumholtz H.M., Larson M., Levy D. Prognosis of left ventricular geometric patterns in the Framingham Heart Study. JAm Coll Cardiol 1995, 25:879-884.
86. Devereux R.B., Wachtell K., Gerdts E., et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004, 292:2350-2356.
87. Okin P.M., Wachtell K., Devereux R.B., et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA 2006, 296:1242-1248.
88. Okin P.M., Devereux R.B., Jern S., et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004, 292:2343-2349.
89. Artham S.M., Lavie C.J., Milani R.V., et al. Clinical impact of left ventricular hypertrophy and implications for regression. Prog Cardiovasc Dis 2009, 52:153-167.
90. Wachtell K., Greve A. Structural and functional cardiac changes are target organ damage that increases risk of atrial fibrillation. JAm Coll Cardiol 2014, 63(19):2014-2015.
91. Kuruvilla S., Janardhann R., Antokowiak P., et al. Increased extracellular volume and altered mechanics are associated with LVH in hypertensive heart disease, not hypertension alone. JAm Coll Cardiol 2015, 8:172-180.
92. Gaasch W., Aurigemma G. CMR imaging of extracellular volume and myocardial strain in hypertensive heart disease. JAm Coll Cardiol 2015, 8:181-183.
93. Raman S.V., Shah M., McCarthy B., et al. Multi-detector row cardiac computed tomography accurately quantifies right and left ventricular size and function compared with cardiac magnetic resonance. Am Heart J 2006, 151(3):736-744.
94. Gradman A.H., Alfayoumi F. From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease. Prog Cardiovasc Dis 2006, 48:326-341.
95. Moser M., Herbert P.R. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. JAm Coll Cardiol 1996, 27(5):1214-1218.
96. Rials S., Wu Y., Xu X., et al. Regression of left ventricular hypertrophy with captopril restores normal ventricular action potential duration, dispersion of refractoriness, and vulnerability to inducible ventricular fibrillation. Circulation 1997, 96:1330-1336.
97. Solomon S.D., Appelbaum E., Manning W.J., et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor block losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009, 119:530.
98. Pierdomenico S.D., Lappennda D., Cuccurollo F. Regression of echocardiographic left ventricular hypertrophy after 2 years of therapy reduces cardiovascular risk in patients with essential hypertension. Am J Hypertens 2008, 21:464.
99. Ang D.S., Fahey T.P., Wright G.A., et al. Development and validation of a clinical score to identify echocardiographic left ventricular hypertrophy in patients with cardiovascular disease. Am J Hypertens 2008, 21:1011.
100. Schirmer S., Sayed M., Reil J., et al. Improvements in left ventricular hypertrophy and diastolic function following renal denervation. JAm Coll Cardiol 2014, 63:1916-1923.
101. Bakris G., Nathan S. Renal denervation and left ventricular mass regression: a benefit beyond blood pressure reduction?. JAm Coll Cardiol 2014, 63:1924-1925.
102. Takeuchi M., Borden W.B., Nakai H., et al. Reduced and delayed untwisting of the left ventricle in patients with hypertension and left ventricular hypertrophy: a study using two-dimensional speckle tracking imaging. Eur Heart J 2007, 28:2756-2762.
103. Gardin J.M., Lauer M.S. Left ventricular hypertrophy: the next treatable, silent killer?. JAMA 2004, 292:2396-2398.